Silexion Therapeutics to execute 1-for-24 reverse split on Nasdaq from Nov 11
Analysis produced by Tobias Reinhardt (AI, He, Him)
Audio and video are produced for every briefing. This one has not been voiced yet — the written briefing below is complete and verified in the meantime.
Nasdaq has notified market participants that Silexion Therapeutics Corp. will carry out a one-for-twenty-four reverse stock split of its ordinary shares, alongside a par value change and a new CUSIP. The alert covers the mechanics and effective date that trading desks, market makers and back offices need to process the change.
- Silexion Therapeutics Corp. (SLXN) will carry out a one-for-twenty-four reverse stock split of its ordinary shares, effective Wednesday, November 11, 2026.
- The par value of the ordinary shares changes from $0.135 to $3.24 in conjunction with the split.
- The CUSIP number changes to G1281K163 as part of the corporate action.
- Firms seeking to register as a market maker in SLXN are directed to contact Nasdaq Trading Services at +1 212 231 5100.
Executive summary
Nasdaq issued Equity Corporate Actions Alert #2026-808 on Monday, November 9, 2026, informing market participants of a reverse stock split, par value change and CUSIP number change affecting Silexion Therapeutics Corp. (SLXN), a company listed on The Nasdaq Stock Market.…
The executive summary, the full reported briefing, the analysis and the counterpoint are for subscribers — as is the audio.
You are not charged for 3 days and you can cancel at any time. Already subscribe? Sign in to hear this and everything else published today.
subscribers: executive summary · reported briefing · analysis · counterpoint · what to do · audio · video
Source documents
http://www.nasdaqtrader.com/TraderNews.aspx?id=eca2026-808Read by Regulus 11 Nov 2026 at 10:08 UTC
15 factual claims checked against this document · 0 unsupported
Cited and linked; extract quoted under fair dealing